Interpace Biosciences, Inc.
IDXG
$1.14
-$0.03-2.56%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 17.21% | 16.87% | 11.04% | 19.98% | 25.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.21% | 16.87% | 11.04% | 19.98% | 25.74% |
| Cost of Revenue | 13.49% | 6.04% | 6.32% | 8.05% | 10.08% |
| Gross Profit | 19.44% | 24.23% | 14.13% | 28.63% | 37.43% |
| SG&A Expenses | 7.90% | 3.58% | -2.35% | -0.15% | -2.51% |
| Depreciation & Amortization | -- | -97.66% | -82.22% | -57.17% | -32.13% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.61% | 1.58% | -1.62% | 1.09% | 1.10% |
| Operating Income | 104.59% | 359.77% | 542.92% | 290.22% | 203.20% |
| Income Before Tax | 204.69% | 653.89% | 327.04% | 156.56% | 139.09% |
| Income Tax Expenses | -76.47% | 0.00% | 750.00% | 21.43% | -39.29% |
| Earnings from Continuing Operations | 206.80% | 643.87% | 325.87% | 155.98% | 138.62% |
| Earnings from Discontinued Operations | 21.29% | 65.87% | 98.59% | 97.78% | 98.07% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 242.99% | 454.24% | 125.96% | 110.70% | 108.90% |
| EBIT | 104.59% | 359.77% | 542.92% | 290.22% | 203.20% |
| EBITDA | 68.53% | 164.71% | 133.98% | 9,315.09% | 489.77% |
| EPS Basic | 214.76% | 447.17% | 125.25% | 110.45% | 108.71% |
| Normalized Basic EPS | 199.21% | 689.14% | 331.76% | 152.63% | 136.98% |
| EPS Diluted | 104.55% | 444.54% | 125.14% | 110.35% | 108.64% |
| Normalized Diluted EPS | 86.36% | 686.56% | 330.79% | 152.51% | 136.93% |
| Average Basic Shares Outstanding | 1.61% | 1.53% | 1.55% | 1.66% | 1.88% |
| Average Diluted Shares Outstanding | 264.13% | 1.94% | 1.79% | 1.81% | 1.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |